Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at HC Wainwright

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $7.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 129.51% from the company’s previous close.

Separately, EF Hutton Acquisition Co. I upgraded Anixa Biosciences to a “strong-buy” rating in a report on Wednesday, August 7th.

Anixa Biosciences Stock Performance

Shares of ANIX stock opened at $3.05 on Tuesday. The stock’s fifty day moving average is $3.26 and its 200-day moving average is $2.99. The stock has a market capitalization of $98.15 million, a PE ratio of -7.82 and a beta of 0.84. Anixa Biosciences has a 52 week low of $2.14 and a 52 week high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Friday, September 6th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. As a group, analysts forecast that Anixa Biosciences will post -0.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Anixa Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Concorde Asset Management LLC acquired a new position in Anixa Biosciences in the second quarter valued at about $31,000. Virtu Financial LLC lifted its stake in Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after buying an additional 5,183 shares during the period. Nations Financial Group Inc. IA ADV lifted its stake in Anixa Biosciences by 50.0% in the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after buying an additional 7,500 shares during the period. International Assets Investment Management LLC lifted its stake in Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after buying an additional 23,800 shares during the period. Finally, Tyler Stone Wealth Management lifted its stake in Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after buying an additional 21,008 shares during the period. Institutional investors and hedge funds own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.